Testis Cancer Testicular
Conditions
Interventions
1. Group A: Chemotherapy with etoposide, ifosfamide, mensa and CDDP (PEI) or etoposide, ifosfamide, mensa and CDDP (VEIP). Treatment cycle repeated every 21 days for four cycles.
2. Group B: Chemother
Sponsors
Institut Gustave-Roussy (France)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Males aged >16 years 2. Germ cell tumours, either testicular or extragonadal 3. Platinum combination chemotherapy as first line chemotherapy 4. Remission after complete response from first line chemotherapy 5. Partial responder patients after first line chemotherapy, including patients with resection of viable malignancy after first line chemotherapy with elevated tumour markers 6. World Health Organisation (WHO) performance status grade 0-2 7. Seminoma patients relapsing after complete response after cisplatin-based chemotherapy or partial response under cisplatin-based chemotherapy 8. Refactory patients are to be excluded 9. Patients with pure seminoma treated with carboplatin are excluded 10. No other malignancy 11. No medical contraindications to protocol treatments
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
France
Outcome results
None listed